Advertisement
Advertisement

SMMT

SMMT logo

Summit Therapeutics Inc. Common Stock

15.11
USD
Sponsored
-0.37
-2.39%
Jul 10, 12:29 UTC -4
Open

SMMT Earnings Reports

Positive Surprise Ratio

SMMT beat 3 of 15 last estimates.

20%

Next Report

Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$0.28
Implied change from Q1 26 (Revenue/ EPS)
--
/
+16.67%
Implied change from Q2 25 (Revenue/ EPS)
--
/
+133.33%

Summit Therapeutics Inc. Common Stock earnings per share and revenue

On Apr 30, 2026, SMMT reported earnings of -0.24 USD per share (EPS) for Q1 26, missing the estimate of -0.18 USD, resulting in a -33.26% surprise. Revenue reached --, compared to an expected 72.11 thousand, with a -100.00% difference. The market reacted with a -24.91% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 12 analysts forecast an EPS of -0.28 USD, with revenue projected to reach -- USD, implying an increase of 16.67% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Cybin Inc. Common Stock
Report Date
Jun 29, 2026 For Q4 26
Estimate
-$0.91
Actual
-$1.16
Surprise
-27.08%
FAQ
For Q1 2026, Summit Therapeutics Inc. Common Stock reported EPS of -$0.24, missing estimates by -33.26%, and revenue of $0.00, -100% below expectations.
The stock price moved down -24.91%, changed from $21.46 before the earnings release to $16.11 the day after.
The next earning report is scheduled for Aug 10, 2026.
Based on 12 analysts, Summit Therapeutics Inc. Common Stock is expected to report EPS of -$0.28 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement